According to the USA Food and Drug Administration, quality of life (QOL) and/or survival are a priority for new anticancer drug approval. This study was performed to review approaches to QOL in randomized controlled clinical trials (RCCTs) and to survey the use of such measures in trials.
Material and Methods
A literature survey was carried out using the Medline/Medscape, Embase, Cochrane Library, and Ovid databases. Included in the survey were all publications in the set period (from 1966 to June 2005) with “quality of life” in the title or in the abstract in the field of “randomized, controlled clinical trials”. Each trial was evaluated according to the level of importance of QOL as a measure of outcome (primary, important and secondary) and was analyzed using the quality scoring system reported by Nicolucci et al. with some items regarding QOL.
Results
Four hundred and five RCCT articles in the oncology setting were found. Fifty-six of the 405 (13.8%) publications had QOL as primary end point. The overall quality score of these trials ranged from 40% to 100%, with a median overall score of 80%. The overall score was correlated with the year of publication (P = 0.007), the type of journal (P = 0.05), the presence of a biostatistician among the authors (P = 0.001), and the number of participating institutions (P = 0.009).
Conclusions
More attention to QOL in all components of RCCTs (design, choice of instruments, data management and processing) is required from both clinicians and statisticians.
GuyattG.H., SanderJ.O., FeenyD., PatrikD.L.: Measuring quality of life in clinical trials: a taxonomy and review.CMAJ,140: 1441–1448, 1989.
2.
BeitzJ., GneccoC., JusticeR.: Quality of life end points in cancer clinical trials. The US Food and Drug Administration perspective.J Natl Cancer Inst,20: 7–9, 1996.
3.
JohnsonJ.R., TempleR.: Food and Drug Administration requirements for approval of new anticancer drugs.Cancer Treat Rep,69: 1155–1159, 1985.
4.
ZwindermanH.A.: Statistical analysis of longitudinal quality of life data with missing measurements.Qual Life Res,1: 219–224, 1992.
5.
SchumacherM., OlschewskiM., SchulgenG.: Assessment of quality of life in clinical trials.Stat Med,10: 1915–1930, 1991.
6.
CoxD.R., FitzpatrickR., FletcherA.E., GoreS.M., SpiegelhalterD.J., JonesD.R.: Quality of life assessment: can we keep it simple?J R Statist Soc,155: 353–393, 1992.
7.
NicolucciA., GrilliR., AlexanianA.A., ApoloneG., TorriV., LiberatiA.: Quality, evolution, and clinical implications of randomized controlled trials on the treatment of lung cancer.JAMA,262: 2101–2105, 1989.
8.
SchipperH., ClinchJ., McMurrayA., LevittM.: Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: development and validation.J Clin Oncol,2: 472–483, 1984.
9.
SelbyP.J., ChapmanJ.A.W., Etazadi-AmoliJ., DalleyD., BoydN.F.: The development of a method for assessing the quality of life of cancer patients.Br J Cancer,50: 13–22, 1984.
10.
PadillaG.V., PresantC., GrantM., MetterG., LipsettJ., HeideF.: Quality of life index for patients with cancer.Res Nurs Health,6: 117–126, 1984.
11.
SpitzerW.O., DobsonA.J., HallJ., ChestermanE., LeviJ., ShepherdR., BattistaR.N., CatchloveB.R.: Measuring the quality of life of cancer patients. A concise QL-index for use by physicians.J Chron Dis,34: 595–597, 1981.
12.
AaronsonN.K., BullingerM., AhmedzaiS.: A modular approach to quality-of-life assessment in cancer clinical trials.Recent Results Cancer Res,111: 231–249, 1988.
13.
De HaesJ.: Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptoms Check List.Br J Cancer,62: 1034–1038, 1990.
14.
ZigmondA.: The Hospital Anxiety and Depression Scale.Acta Psychol Scand,67: 361–370, 1983.
15.
BradyM.J., CellaD.F., MoF., BonomiA.E., TulskyD.S., LloydS.R., DeasyS., CobleighM., ShiomotoG.: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.J Clin Oncol,15: 974–986, 1997.
16.
FerrellB., WisdomC., WenzlC., BrownJ.: Effects of controlled-released morphine on quality of life for cancer pain.Oncol Nurs Forum,16: 521–526, 1989.
17.
Della CunaG.R., PellegriniA., PiazziM.: Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group.Eur J Cancer Clin Oncol,25: 1817–1821, 1989.
18.
KiebertG.M., HannekeJ., de HaesC.J., KievitJ., van de VeldeC.J.: Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer.Eur J Cancer,26: 1038–1042, 1990.
19.
Van Holten-VerzantvoortA.T., ZwindermanA.H., AaransonN.K., HermansJ., van EmmerikB., van DamF.S., van den BosB., BijvoetO.L., CletonF.J.: The effect of supportive Pamidronate treatment on aspects of quality of life of patients with advanced breast cancer.Eur J Cancer,27: 544–549, 1991.
20.
BellerE., TattersallM., LumleyT., LeviJ., DalleyA., OlverI., PageJ., AbdiE., WynneC., FriedlanderM., BoadleD., WheelerH., MargrieS., SimesR.J.: Improved quality of life with mege-strol acetate in patients with endocrine-insensitive advanced cancer: a randomized placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group.Ann Oncol,8: 277–283, 1997.
21.
Van AndelG., KurthK.H., RietbroekR.L., van de Velde-MuusersJ.A.: Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate - is it feasible?Eur Urol,38: 259–264, 2000.
22.
AndersonH., HopwoodP., StephensR.J., TatcherN., CottierB., NicholsonM., MilroyR., MaughanT.S., FalkS.J., BondM.G., BurtP.A., ConnolyC.K., McIllmurrayM.B., CarmichaelJ.: Gemcitabine plus best supportive care (BSC) vs BSC inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer.Br J Cancer,83: 447–453, 2000.
23.
FowlerJEJr.Viadur Study Group: Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer.Urology,58: 430–434, 2001.
24.
SailerM., FuchsK.H., FeinM., ThiedeA.: Randomized clinical trial comparing quality of life after straight and pouch coloanal reconstruction.Br J Surg,89: 1108–1117, 2002.
25.
OsobaD., SlamonD.J., BurchmoreM., MurphyM.: Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.J Clin Oncol,20: 3106–3113, 2002.
26.
KornblithA.B., HerndonJE2nd, SilvermanL.R., DemakosE.P., Odchimar-ReissigR., HollandJ.F., PowellB.L., DeCastroC., EllertonJ., LarsonR.A., SchifferC.A., HollandJ.C.: Impact of azacytidine on the quality of life of patients with myelodys-plastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.J Clin Oncol,20: 2441–2452, 2002.
27.
KonoK., IizukaH., SekikawaT., SugaiH., TakahashiA., FujiiH., MatsumotoY.: Improved quality of life with jejunal pouch reconstruction after total gastrectomy.Am J Surg,185: 150–154, 2003.
FischM.J., TitzerM.L., KristellerJ.L., ShenJ., LoehrerP.J., JungS.H., PassikS.D., EinhornL.H.: Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being - a Hoosier Oncology Group Study.J Clin Oncol,21: 2754–2759, 2003.
30.
WongG.Y., SchroederD.R., CamsP.E., WilsonJ.L., MartinD.P., KinneyM.O., MantillaC.B., WarnerD.O.: Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial.JAMA,291: 1092–1099, 2004.
31.
Pistevou-GompakiK., KoulouliasV.E., VarverisC., Mystaki-douK., GeorgakopoulosG., EleftheriadisN., GompakisN., KouvarisJ.: Radiotherapy plus either transdermal fentanyl or paracetamol and codeine for painful bone metastases: a randomised study of pain relief and quality of life.Curr Med Res Opin,20: 159–163, 2004.
32.
PiaoB.K., WangY.X., XieG.R., MansmannU., MatthesH., BeuthJ., LinH.S.: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.Anticancer Res,24: 303–309, 2004.
33.
SemiglasovV.F., StepulaV.V., DudovA., LehmacherW., MengsU.: The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial.Anticancer Res,24: 1293–1302, 2004.
34.
HornsM.Y., Essink-BotM.L., BorsboomG.J., SteyerbergE.W., SiersemaP.D.: Quality of life after palliative treatment for oesophageal carcinoma - a prospective comparison between stent placement and single dose brachytherapy.Eur J Cancer,40: 1862–1871, 2004.
35.
AhlesT.A., HerndonJE2nd, SmallE.J., VogelzangN.J., KornblithA.B., RatainM.J., StadlerW., PalchakD., MarshallM.E., WildingG., PetrylakD., HollandJ.C.: Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup 0159/Cancer and Leukemia Group B 9480.Cancer,101: 2202–2208, 2004.
36.
ZiolkoE., KnopikJ., BuciorJ., FoltynW., Jastrzebska-OkonK., TomczykA., KempinskiM.: Evaluation of the usefulness and effectiveness of anxiolytic therapies in neoplastic diseases.Pol Merkuriusz Lek,16: 561–564, 2004.
37.
ErridgeS.C., GazeM.N., PriceA., KellyC.G., KerrG.R., CullA., MacDougallR.H., HowardG.C., CowieV.J., GregorA.: Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules.Clin Oncol (R Coll Radiol),17: 61–67, 2005.
38.
MacGregorC.A., CanneyP.A., PattersonG., McDonaldR., PaulJ.: A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer.Eur J Cancer,41: 708–714, 2005.
39.
MarijnenC.A., van de VeldeC.J., PutterH., van den BrinkM., MaasC.P., MartijnH., RuttenH.J., WiggersT., KranenbargE.K., LeerJ.W., StiggelboutA.M.: Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial.J Clin Oncol,23: 1847–1858, 2005.
40.
RingashJ., PerkinsG., BrierleyJ., LockwoodG., IslamM., Cat-tonP., CummingsB., KimJ., WongR., DawsonL.: IMRT for adjuvant radiation in gastric cancer: A preferred plan?Int J Radiat Oncol Biol Phys,63: 732–738, 2005.
41.
WardleyA., DavidsonN., Barrett-LeeP., HongA., MansiJ., DodwellD., MurphyR., MasonT., CameronD.: Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.Br J Cancer,92: 1869–1876, 2005.
42.
MarchinD.: Suggestion for the presentation of quality of life data from clinical trial.Stat Med,17: 711–724, 1998.
43.
CurranD., BacchiM., hsu SchmitzS.F., MolenberghsG., SylvesterR.J.: Identifying the types of missingness in quality of life data from clinical trials.Stat Med,17: 739–756, 1998.
44.
TassinariD., PanziniI., SartoriS., RavaioliA.: Surrogate outcomes in quality-of-life research: where will we end up?J Clin Oncol,21: 1894–1895, 2003.
45.
TroxelA.B., FaircloughD.L., CurranD., HahnE.A.: Statistical analysis of quality of life with missing data in cancer clinical trials.Stat Med,17: 653–666, 1998.
46.
SimesR.J., GreatorexV., GebskiV.J.: Practical approches to minimize problems with missing quality of life data.Stat Med,17: 725–737, 1998.
47.
GoldhirschA., GelberR.D., SimesR.J., GlasziouP.P., CoatesA.: Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis.J Clin Oncol,7: 36–44, 1989.
48.
FlemingT.L., De MetsD.L.: Surrogate endpoints in clinical trials: are we being misled?Ann Intern Med,125: 605–613, 1996.
